This site is intended only for healthcare professionals resident in the Republic of Ireland

Search

Menu

Close

Sign in or RegisterLog out
Our medicinesTherapy areasExplore contentExplore contentMaterialsVideosPodcastsLet’s connectLet's connectContact usSign up

Menu

Close

AboutInfliximabWhat is infliximabMechanism of actionBiosimilarsApprovalOverviewPosition statementsECCOEULARESPGHANDosing & SwitchingDosingIV dosingAdministration & storageIV administrationStorageSafety informationImportant safety informationSwitchingConsiderations for switchingSafety informationImportant safety informationSafety informationImportant safety informationClinical EvidenceRandomised controlled trial evidenceSummary: randomised controlled trial evidenceSupport & ResourcesMaterials
Position statements: ECCO

The European Crohn’s and Colitis Organisation (ECCO) is a European medical association focused on IBD1

ECCO released an updated Position Statement on the Use of Biosimilars in 2017 that supports the use of INFLECTRA® (CT-P13*/infliximab) in appropriate patients with IBD2

​​​​​​​“Since biosimilars were introduced in the EU market in early 2015, more data from IBD patients have supported the biosimilarity of biosimilar infliximab CT-P13 and the reference product, with no significant differences in terms of efficacy or safety, in either naïve or switched patients in cohort studies”2
Example Text

The updated ECCO position statement also encourages the important role of healthcare professionals in patient counselling on biosimilars2

“Healthcare professionals have the responsibility to ensure that all information is given to the patient to promote shared decision-making, confirming informed consent to treatment and evidence-based patient choice”2
Example Text
CT-P13 is marketed under different brand names including INFLECTRA® and REMSIMA™.IBD, Inflammatory bowel disease.

Please refer to the INFLECTRA® Summary of Product Characteristics for full prescribing information

References:ECCO web site. About ECCO. Available at: https://www.ecco-ibd.eu/about-ecco.html. Accessed May 2023Danese S, et al. J Crohns Colitis 2017;11(1):26-34.
Position statements INFLECTRA® dosing

Read about dosing and administration of INFLECTRA®

Find out more Loading

Legal Category: S1A
Further information is available upon request

PP-IFA-IRL-0146 May 2023

Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)
 

Adverse events should also be reported to Pfizer Medical Information on 1800 633 363

PfizerPro AccountPfizerPro Account

Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.

Sign in or RegisterRegisterAccountLog out

This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie

 

This website is brought to you by Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland. Registered in the Republic of Ireland No. 127002.

 

Copyright © 2023 Pfizer Limited. All rights reserved.

PP-UNP-IRL-0176. January 2023
For Healthcare Professionals in the Republic of Ireland *

The information contained on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland.

I confirm that I am a healthcare professional resident in the Republic of Ireland.*

I accept and agree to the terms of use.*

If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland.

PP-UNP-IRL-0176. January 2023

Yes No
You are now leaving PfizerPro
You are now leaving PfizerPro Ireland. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer. Pfizer accepts no responsibility for the content or services of the linked site.
PP-UNP-IRL-0176. January 2023